Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CEO Lynn Seely purchased 175,000 shares of the stock in a transaction on Friday, March 14th. The shares were purchased at an average cost of $0.61 per share, for a total transaction of $106,750.00. Following the acquisition, the chief executive officer now directly owns 712,500 shares of the company's stock, valued at approximately $434,625. This represents a 32.56 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Lyell Immunopharma Stock Performance
LYEL stock traded up $0.05 during mid-day trading on Friday, reaching $0.58. 1,287,155 shares of the stock traded hands, compared to its average volume of 1,045,811. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15. The stock has a market capitalization of $170.79 million, a PE ratio of -0.73 and a beta of -0.41. The business has a 50-day moving average price of $0.61 and a two-hundred day moving average price of $0.89.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, equities analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Thursday, March 13th.
Get Our Latest Stock Analysis on Lyell Immunopharma
Hedge Funds Weigh In On Lyell Immunopharma
Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its stake in shares of Lyell Immunopharma by 1,285.5% during the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company's stock valued at $490,000 after purchasing an additional 329,205 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma during the 3rd quarter worth $52,000. Erste Asset Management GmbH bought a new stake in Lyell Immunopharma during the third quarter valued at about $82,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Lyell Immunopharma during the third quarter valued at about $52,000. Finally, Centiva Capital LP purchased a new position in Lyell Immunopharma in the third quarter valued at about $31,000. Hedge funds and other institutional investors own 66.05% of the company's stock.
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Stories
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
